Comparative Pharmacology
Head-to-head clinical analysis: CYCLOCORT versus U CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOCORT versus U CORT.
CYCLOCORT vs U-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
U-CORT (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and subsequent anti-inflammatory, immunosuppressive, and metabolic effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production and immune cell migration.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
U-CORT (hydrocortisone) 100 mg intravenous bolus, followed by 100 mg intravenous every 8 hours for 48 hours, then taper as clinically indicated.
None Documented
None Documented
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Terminal half-life approximately 1.6-2.2 hours; clinically used as short-acting topical corticosteroid.
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Primarily hepatic metabolism; inactive metabolites excreted renally (60-70%) and biliary/fecal (20-30%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid